Cardiovascular activity of the chiral xanthone derivatives

被引:21
|
作者
Szkaradek, Natalia [1 ]
Rapacz, Anna [2 ]
Pytka, Karolina [2 ]
Filipek, Barbara [2 ,3 ]
Zelaszczyk, Dorota [1 ]
Szafranski, Przemyslaw [4 ]
Sloczynska, Karolina [5 ]
Marona, Henryk [1 ]
机构
[1] Jagiellonian Univ, Coll Med, Fac Pharm, Chair Organ Chem,Dept Bioorgan Chem, PL-30688 Krakow, Poland
[2] Jagiellonian Univ, Coll Med, Fac Pharm, Dept Pharmacodynam, PL-30688 Krakow, Poland
[3] Jagiellonian Univ, Coll Med, Fac Pharm, Lab Pharmacol Screening, PL-30688 Krakow, Poland
[4] Jagiellonian Univ, Coll Med, Fac Pharm, Chair Organ Chem, PL-30688 Krakow, Poland
[5] Jagiellonian Univ, Coll Med, Fac Pharm, Dept Pharmaceut Biochem, PL-30688 Krakow, Poland
关键词
Antiarrhythmic; Hypotensive; Adrenoceptor; Xanthone; Synthesis; PHARMACOLOGICAL-PROPERTIES; PIPERAZINE DERIVATIVES; ADRENOLYTIC ACTIVITY; DRUGS; AFFINITIES; RECEPTORS; ARTICLE; COPPER;
D O I
10.1016/j.bmc.2015.09.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of 6 derivatives of xanthone were synthesized and evaluated for cardiovascular activity. The following pharmacological experiments were conducted: the binding affinity for adrenoceptors, the influence on the normal electrocardiogram, the effect on the arterial blood pressure, the effect on blood pressor response and prophylactic antiarrhythmic activity in adrenaline induced model of arrhythmia (rats, iv). Two compounds revealed nanomolar affinity for alpha(1)-adrenoceptor which was correlated with the strongest cardiovascular (antiarrhythmic and hypotensive) activity in animals' models. They were enantiomers of previously described (R, S)-4-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)- 9H-xanthen-9-one hydrochloride and revealed similar antiarrhythmic potential in adrenaline induced model of arrhythmia in rats after intravenous injection (ED50 = 0.53 mg/kg and 0.81 mg/kg, respectively). These values were lower than values obtained for reference drug urapidil. These compounds were more active in this experiment than urapidil (ED50 = 1.26 mg/kg). The compound 5 administered iv at doses of 0.62-2.5 mg/kg at the peak of arrhythmia prevented and/or reduced the number of premature ventricular beats in a statistically significant manner. The ED50 value was 1.20 mg/kg. The S-enantiomer (6) given at the same doses did not show therapeutic antiarrhythmic activity in this model. These compounds significantly decreased the systolic and diastolic blood pressure throughout the whole observation period in anesthetized, normotensive rats. The studied enantiomers showed higher toxicity than urapidil, but imperceptibly higher that another cardiovascular drugs, that is, carvedilol or propranolol. They were also evaluated for mutagenic potential in the Ames (Salmonella) test. It was found that at the concentrations tested the compounds were non mutagenic when compared to solvent control. Results were quite promising and suggested that in the group of xanthone derivatives new potential antiarrhythmics and hypotensives might be found. (c) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6714 / 6724
页数:11
相关论文
共 50 条
  • [1] Antiprotozoal Activity of Xanthone Derivatives
    Micheletti, Ana Camila
    Honda, Neli Kika
    de Oliveira, Paola Dias
    de Lima, Denis Pires
    Beatriz, Adilson
    de Albuquerque, Sergio
    ORBITAL-THE ELECTRONIC JOURNAL OF CHEMISTRY, 2020, 12 (03): : 127 - 132
  • [2] ANTIOXIDANT ACTIVITY OF XANTHONE DERIVATIVES
    Francik, Renata
    Szkaradek, Natalia
    Zelaszczyk, Dorota
    Marona, Henryk
    ACTA POLONIAE PHARMACEUTICA, 2016, 73 (06): : 1505 - 1509
  • [3] Anticonvulsant activity of some xanthone derivatives
    Marona, Henryk
    Pekala, Elzbieta
    Antkiewicz-Michaluk, Lucyna
    Walczak, Maria
    Szneler, Edward
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (15) : 7234 - 7244
  • [4] Central activity of new xanthone derivatives with chiral center in some pharmacological tests in mice.
    Jastrzebska-Wiesek, M
    Librowski, T
    Czarnecki, R
    Marona, H
    Nowak, G
    POLISH JOURNAL OF PHARMACOLOGY, 2003, 55 (03): : 461 - 465
  • [5] An Update on the Anticancer Activity of Xanthone Derivatives: A Review
    Kurniawan, Yehezkiel Steven
    Priyangga, Krisfian Tata Aneka
    Jumina
    Pranowo, Harno Dwi
    Sholikhah, Eti Nurwening
    Zulkarnain, Abdul Karim
    Fatimi, Hana Anisa
    Julianus, Jeffry
    PHARMACEUTICALS, 2021, 14 (11)
  • [7] Antiarrhythmic and antihypertensive activity of some xanthone derivatives
    Marona, Henryk
    Librowski, Tadeusz
    Cegla, Marek
    Erdogan, Cankat
    Sahin, Nefise Oezlen
    ACTA POLONIAE PHARMACEUTICA, 2008, 65 (03): : 383 - 390
  • [8] Aminoalkanolic derivatives of xanthone with potential antiepileptic activity
    Marona, H
    Gorka, Z
    Szneler, E
    PHARMAZIE, 1998, 53 (04): : 219 - 223
  • [9] Design, synthesis and cardiovascular evaluation of some aminoisopropanoloxy derivatives of xanthone
    Kubacka, M.
    Szkaradek, N.
    Mogilski, S.
    Panczyk, K.
    Siwek, A.
    Grybos, A.
    Filipek, B.
    Zmudzki, P.
    Marona, H.
    Waszkielewicz, A. M.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (13) : 3773 - 3784
  • [10] New chiral stationary phases based on xanthone derivatives for liquid chromatography
    Fernandes, Carla
    Tiritan, Maria Elizabeth
    Cravo, Sara
    Phyo, Ye' Zaw
    Kijjoa, Anake
    Silva, Artur M. S.
    Cass, Quezia B.
    Pinto, Madalena M. M.
    CHIRALITY, 2017, 29 (08) : 430 - 442